News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Authorities weigh further yen support, driving FX volatility and influencing Asian market trading.
  • Investors await U.S. CPI and upcoming retail and producer price reports that could shift rate expectations and equity flows.
  • Iran and Oman hold tentative talks on Strait of Hormuz transit management, easing some regional shipping risk.
  • Australian and Norwegian central banks deliver decisions today, adding near-term policy risk for rates-sensitive assets.
  • Lotus Bakeries jumps after H1 results: revenue up 14%, net profit €98.1m, underlying EBIT margin 17.5%.
  • Revolution Medicines flagged as a speculative oncology trade after Breakthrough Therapy recognition and fresh institutional buying.

Latest Articles

Toast Bounce Trade: Buy the FCF Engine Beneath the POS Sell-Off

Toast Bounce Trade: Buy the FCF Engine Beneath the POS Sell-Off

Toast is a vertically integrated restaurant software and payments platform that just produced record free cash flow while the stock trades well below its 52-week high. This trade idea targets a mid-term swing: a buy near $29.50 with a $40 target and a $25 stop, banking on FCF strength, >160k locations and an attractive EV-to-ARR setup to drive a re…

Ocugen to Present at April 2026 Investor and Industry Conferences

Ocugen to Present at April 2026 Investor and Industry Conferences

Ocugen, Inc., a biotechnology company focusing on gene therapies for blindness diseases, announced that its executives will present at two prominent biotech conferences in April 2026. The presentations will cover their novel modifier gene therapy platform and near-term catalysts, including the planned Biologics License Application (BLA) submission …

Altisource Announces First Quarter 2026 Financial Results

Altisource Announces First Quarter 2026 Financial Results

Altisource Portfolio Solutions S.A. announced its Q1 2026 financial results, highlighting a 10% increase in service revenue to $45.1 million, substantial improvements in pretax earnings and operating cash flow compared to Q1 2025. The Origination segment saw a 71% growth in service revenue and a 166% increase in adjusted EBITDA, fueled by sales win…

Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform

Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform

Purple Biotech announced the establishment of a Scientific Advisory Board (SAB) comprising leading experts in T-cell and NK cell engager therapies and tumor immunology. The SAB will advise the company on the development of its CAPTN-3 tri-specific antibody platform aimed at maximizing anti-cancer efficacy while minimizing toxicity by activating imm…

Nasdaq Reports First Quarter 2026 Results; Strong Execution Drives Double-Digit Net Revenue Growth Across All Divisions

Nasdaq Reports First Quarter 2026 Results; Strong Execution Drives Double-Digit Net Revenue Growth Across All Divisions

Nasdaq, Inc. reported strong financial results for Q1 2026, delivering 14% net revenue growth to $1.4 billion and 33% GAAP diluted earnings per share growth year-over-year. All business divisions—Financial Technology, Capital Access Platforms, and Market Services—showed robust organic growth, driven by increased client adoption, expansion of AI-dri…

Valley National Bancorp Announces First Quarter 2026 Results

Valley National Bancorp Announces First Quarter 2026 Results

Valley National Bancorp reported first quarter 2026 net income of $163.9 million, or $0.28 per diluted common share, reflecting a solid financial performance with a 5.5% annualized loan growth and increased deposit balances. The bank maintained a stable net interest margin of 3.17% and continued to diversify its loan portfolio while investing in AI…

ConnectOne Bancorp, Inc. Reports First Quarter 2026 Results

ConnectOne Bancorp, Inc. Reports First Quarter 2026 Results

ConnectOne Bancorp, Inc. reported robust first quarter 2026 financial results characterized by a 12 basis point increase in net interest margin to 3.39%, 10% annualized loan and deposit growth, and an 8.3% increase in common stock dividend per share. The merger with First of Long Island Corporation continues to contribute positively to earnings, as…

Malibu Boats, Inc. Announces Earnings Release Date and Conference Call Information for Third Quarter Fiscal 2026 Financial Results

Malibu Boats, Inc. Announces Earnings Release Date and Conference Call Information for Third Quarter Fiscal 2026 Financial Results

Malibu Boats, Inc. will release its third quarter fiscal 2026 financial results on May 7, 2026, after market close, followed by a management conference call. The call will be hosted by CEO Steve Menneto and CFO David Black, providing insights into the company's performance. Malibu Boats is a leading manufacturer of recreational powerboats, includin…

Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026

Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026

Tonix Pharmaceuticals presented preclinical data demonstrating that its TNX-1700 (a TFF2-albumin fusion protein) effectively reverses aging-associated gastric inflammation and reduces tumor progression, while TNX-4700 (anti-BTLA monoclonal antibody) showed potent binding and functional antagonism. These developments highlight Tonix's advancing immu…

American Airlines Reports First-Quarter 2026 Financial Results

American Airlines Reports First-Quarter 2026 Financial Results

American Airlines Group Inc. reported a record first-quarter revenue of $13.9 billion in 2026, marking a 10.8% year-over-year increase. The company reduced its total debt to $34.7 billion, the lowest since mid-2015. Despite a GAAP net loss of $382 million due to increased fuel costs, underlying performance improved with a reduced loss excluding spe…

Aeluma to Participate in SPIE Defense + Security Conference

Aeluma to Participate in SPIE Defense + Security Conference

Aeluma, Inc., a US-based semiconductor company focusing on high-performance scalable technologies, announced its participation in the 2026 SPIE Defense + Security Conference. The company will exhibit its disruptive photonic and electronic semiconductor products, highlighting innovations in shortwave infrared sensors and quantum dot lasers. The even…

B2Gold Completes the Sale of its 70% Interest in Fingold

B2Gold Completes the Sale of its 70% Interest in Fingold

B2Gold Corp. has finalized the sale of its 70% interest in Fingold Ventures Ltd. to Agnico Eagle Mines Limited for $325 million in cash. The company expresses eagerness to collaborate with Agnico Eagle in Nunavut, Canada under a new collaboration agreement, aiming to share expertise and operational best practices.

Descartes Acquires Idelic

Descartes Acquires Idelic

Descartes Systems Group has acquired Idelic, a provider of AI-powered driver safety and performance management solutions. This acquisition integrates Idelic's extensive safety data and predictive analytics capabilities into Descartes' Global Logistics Network, enhancing fleet safety and operational efficiency. The deal includes an upfront $28 milli…

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

Psyence Biomedical Ltd. (Nasdaq: PBM) has initiated patient dosing in its Phase IIb clinical trial evaluating NPX-5, a nature-derived psilocybin, for treating Adjustment Disorder in cancer patients undergoing palliative care. The randomized, double-blind trial is conducted across five Australian clinical sites aiming to assess safety, efficacy, and…

Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics provided a business update highlighting completion of enrollment in a Phase 2b trial of RAD 101 with promising 90% concordance to MRI. Positive early Phase 0/1 data for RAD 202 was presented with a recommendation to escalate dosing. Two first-in-human trials were initiated for RV-01 and RAD 402 targeting multiple cancers. Fi…

Genenta signs Definitive Agreements with Sophia High Tech

Genenta signs Definitive Agreements with Sophia High Tech

Genenta Science, listed on Nasdaq under the ticker GNTA and evolving into Saentra Forge, has signed definitive agreements to acquire a majority 51% stake in Italian aerospace and defense manufacturer Sòphia High Tech through two €6 million tranches. Sòphia High Tech specializes in critical mechanical components for space and defense programs and sh…